Selective and noncovalent targeting of RAS mutants for inhibition and degradation.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-22969-5
- By:
- Publication type:
- Article
Works by Fedele, Carmine
Results: 7
1
2
A novel ErbB2 epitope targeted by human antitumor immunoagents.
- Published in:
- FEBS Journal, 2011, v. 278, n. 7, p. 1156, doi. 10.1111/j.1742-4658.2011.08041.x
- By:
- Publication type:
- Article
3
Mechanisms of cardiotoxicity associated with ErbB2 inhibitors.
- Published in:
- Breast Cancer Research & Treatment, 2012, v. 134, n. 2, p. 595, doi. 10.1007/s10549-012-2103-8
- By:
- Publication type:
- Article
4
Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors.
- Published in:
- Breast Cancer Research & Treatment, 2012, v. 133, n. 2, p. 511, doi. 10.1007/s10549-011-1783-9
- By:
- Publication type:
- Article
5
Effects of a human compact anti-ErbB2 antibody on gastric cancer.
- Published in:
- Gastric Cancer, 2014, v. 17, n. 1, p. 107, doi. 10.1007/s10120-013-0244-z
- By:
- Publication type:
- Article
6
αvβ6 integrin is required for TGFβ1-mediated matrix metalloproteinase2 expression.
- Published in:
- Biochemical Journal, 2015, v. 466, n. 3, p. 525, doi. 10.1042/BJ20140698
- By:
- Publication type:
- Article
7
IGF-IR Promotes Prostate Cancer Growth by Stabilizing α<sub>5</sub>β<sub>1</sub> Integrin Protein Levels.
- Published in:
- PLoS ONE, 2013, v. 8, n. 10, p. 1, doi. 10.1371/journal.pone.0076513
- By:
- Publication type:
- Article